Key result
RasGRF1 deletion in diabetic mice reduces fibrosis and improves diastolic function by inhibiting inflammation.
Why the study?
Diabetic cardiomyopathy is characterized by cardiac fibrosis and stiffness leading to heart failure, and the role of RasGRF1 in its development is unclear.
Does RasGRF1 deletion improve cardiac function and reduce fibrosis in a mouse model of streptozotocin-induced diabetic cardiomyopathy?
Comparison
RasGRF1 deficiency (RasGRF1−/−) vs wild-type mice with and without STZ-induced diabetes
Design
Preclinical experimental study in mice
Authors
Loading...
Findings in STZ-diabetic mice warrant clinical caution; leaves open RasGRF1 as a DCM target for prospective studies.
Does RasGRF1 deletion improve cardiac function and reduce fibrosis in a mouse model of streptozotocin-induced diabetic cardiomyopathy?
Deletion of RasGRF1 attenuates myocardial fibrosis and improves diastolic function in a mouse model of diabetic cardiomyopathy by reducing inflammation and oxidative stress.
Tsai et al. (2018) studied Diabetic cardiomyopathy (n=48). RasGRF1 deletion vs. Wild-type mice was evaluated on Diastolic function, cardiac fibrosis, inflammation, and oxidative stress markers. Deletion of RasGRF1 in diabetic mice attenuated myocardial fibrosis and improved diastolic function by inhibiting inflammation and oxidative stress compared to diabetic wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: